At that price you are better off flying to China to get the drug and still have money left over for a nice little vacation while you’re there.
I’m on a drug that costs even more than that. The whole process is bizarre, and appears to be scams all the way down.
What happens for me is that my insurance covers a big chunk of it, which still leaves me with a bill for thousands of dollars. But the drug manufacturer provides me with a card that covers that amount. So the whole thing costs me $5 out of pocket.
The aim seems to be inflating the drug prices to an insane degree to extract more money from the insurance companies. Who then fleece my employer for more money. Who then pay me less, as the insurance is such a huge benefit. And I can’t afford to lose that insurance, so they have a captive employee. And I’m supposed to marvel at all the money I saved.
Sounds like slavery with extra steps.
Thankfully it’s not a lifesaving drug. But yes.
That’s true of a lot of different drugs and treatments, but harder than it sounds.
Sounds crazy when you put it that way
Full Text:
spoiler
China’s world-leading cancer drug makes historic foray into the US amid medicine crisis
An innovative biopharmaceutical medicine from China has been approved by the US Food and Drug Administration (FDA) to treat cancer, as the US turns to China to solve its cancer drug shortages.
Toripalimab, an antibody drug developed by Shanghai Junshi Biosciences, received FDA approval on October 27 to treat nasopharyngeal carcinoma, an aggressive form of cancer that starts behind the nose in the upper part of the throat.
This is the first – and currently only – drug that is approved by the FDA to treat that type of cancer. It is also the first Chinese antibody drug – the development of which requires huge investment and cutting-edge technology – to enter the US market.
The US has been a world leader in biotechnology. American pharmaceutical giants dominate the medicine market at home and internationally.
But in recent years, with a growing fear that the US could expand its sanctions from computer chips to life-saving medicines, the Chinese government and Chinese companies have massively increased investment in research and development of new drugs.
What many did not foresee, though, was that it would be the US looking to China as it experienced difficulty producing its own drugs.
What a US-China biotech war would mean for Hong Kong and the world
[The US is increasingly uncomfortable with its reliance on China-made active pharmaceutical ingredients. Photo: Shutterstock]
Toripalimab, which will be marketed as Loqtorzi in the US, is an antibody drug for PD-1 – a checkpoint inhibitor on immune T-cells.
Malignant tumour cells express a protein that binds to the PD-1 receptor and blocks the body’s immune response. Toripalimab is designed to bind to the PD-1 receptor instead, which allows the immune system to activate and kill tumours.
Junshi partnered with California-based Coherus BioSciences to bring the drug to the US, and it is expected to become available within the first quarter of next year.
“Toripalimab is the first innovative biopharmaceutical independently developed and produced in China approved by the FDA,” Junshi Biosciences stated in a press release on October 29.
“We hope this promising therapy will close a treatment gap for international nasopharyngeal patients struggling to find effective therapies,” Xu Ruihua, a professor and doctor of oncology at the Sun Yat-sen University Cancer Centre and clinical trial lead for the drug, said in the press release.
Last year, a growing list of US sanctions on Chinese tech companies showed signs of crossing into biotechnology.
[The drug will be marketed in the US under the name Loqtorzi and will be used in conjunction with chemotherapy drugs to treat nasopharyngeal cancer. Photo: Handout]
In February, biotech company Wuxi Biologics was added to the unverified list – which forced the company to comply with a huge amount of documentation in order to export from the US.
Wuxi Biologics, which partnered with AstraZeneca to help produce the Covid-19 vaccine, acknowledged that the designation was due to a Covid-induced delay in verification procedures. The company was removed from the list at the end of last year.
Then in September last year, US President Joe Biden signed an executive order to advance domestic biotechnology and biomanufacturing, to “safeguard the United States bioeconomy” against foreign competitors looking to acquire their tech.
While the US has maintained dominance in the sector, according to research consultancy firm McKinsey, in growing industries like biopharmaceuticals – which involves the creation of medicines using biotechnology methods – China is close behind in second place.
In his executive order, Biden stressed not only encouraging R&D in biotechnology, but improving domestic production capacity – an area where the US struggles to compete with China.
But in September this year, the White House announced the country was facing a shortage of 15 cancer drugs “due to manufacturing and supply chain issues”.
[The drug is the first Chinese-developed biopharmaceutical to be approved by the FDA. Photo: AP]
Manufacturing site closures cut the supply of three major drugs – including chemotherapy drug cisplatin – almost in half, Washington said.
To replace the lost supply, the FDA turned to manufacturers outside the US, including Chinese company Qilu Pharmaceutical, to import their cisplatin drug to help solve the “critical shortage”, according to the company.
A survey conducted by the US National Comprehensive Cancer Network in September found that more than half the cancer centres surveyed were still facing shortages of cisplatin.
The FDA originally rejected the approval of toripalimab for distribution in the US last year due to a delay in a required clinical site inspection, according to a Junshi press release last year.
Last week’s approval will allow the drug to be used in combination with chemotherapy drugs cisplatin and gemcitabine for initial treatment of nasopharyngeal cancer.
It is also approved to be used alone for individuals with non-surgically removable tumours that failed to respond to previous chemotherapy treatments.
Due to the location of nasopharyngeal cancer, according to Coherus, surgery is rarely possible to remove tumours, so treating it relies on chemotherapy and radiation.
For those treated with chemotherapy alone, only 20 per cent of patients will have a year of progression-free survival.
Chinese nanoplatform ‘aircraft carrier’ delivers drugs to cancer patients
[Researchers from Donghua University in Shanghai say they have a therapy that attacks tumours by combining strategies and simultaneously inhibiting growth of the primary tumour and tumour metastasis. Image: Shutterstock]
In the clinical trial conducted for initial treatment, those who received toripalimab in combination with other chemotherapy drugs saw their risk of progression or death reduced by 48 per cent, compared to those who received chemotherapy alone.
In terms of overall survival, patients treated with the drug saw a 37 per cent reduction in their risk of death.
Nasopharyngeal carcinoma is rare in the US, with the cancer seen far more in southern China, Southeast Asia, and northern Africa, according to Coherus.
However, toripalimab may soon be approved to treat other forms of cancer as well.
The drug first received approval from the Chinese National Medical Products Administration in 2018 to treat melanoma, and has since been approved for bladder, oesophageal and non-small cell lung cancer.
According to Junshi, there are also clinical studies under way to test its effectiveness for gastric, liver, breast and kidney cancer.
“We are particularly excited to now turn our attention to developing Loqtorzi across multiple tumour types … potentially greatly expanding the number of cancer patients achieving improved survival benefit,” Dennis Lanfear, chief executive of Coherus, said in a press release on the day of the approval.
Li Ning, chief executive of Junshi Biosciences, said plans were being put in place to distribute toripalimab globally, with hopes to introduce the drug to more than 50 countries.
Who is pocketing the price difference:
Junshi partnered with California-based Coherus BioSciences to bring the drug to the US, and it is expected to become available within the first quarter of next year.
Gotta love how the US regulatory regime is structured so middle men always get their taste. It’s like how the US doesn’t produce much in the way of active ingredients, instead US companies import them from China, India, and Poland then package them under their own brand name into pill, capsule, or injectable formulation. During this process the price somehow increases 1,000% to 10,000% over what they paid for the active ingredient.
Ok I got a question. Is there a way other companies can reuse the ingredients/formula for a nonbrand drugs? (example Walmart Great Value for less money)
Yes, but only once the drug is off-patent. ~20 years.
IP law is a plague upon the pharmaceutical industry. It doesn’t just inflate prices, but it stifles research as groups feel they have to try to avoid each other’s parents. Sometimes scientific decisions are justified due to IP rights rather than scientific data. You’d be angered by how often this happens.
And sometimes it takes way longer than that.
There’s even a controversy about whether Google’s PageRank algorithm was intentionally developed as a worse version of (future) Baidu’s RankDex so they could patent it. The fact that there’s any scientific advancement at all under capitalism and the patent system is frankly a miracle.
In practical terms, sure, that actually happens a lot in other countries. In legal terms, i don’t know if it can be done in the US right away or if they have to wait a certain amount of time or jump through god knows how many patent law hoops to not violate the borderline monopoly rights that a lot of these big companies manage to buy for themselves. The US pharma industry is notorious for protecting big corporations from competition by paying lobbyists to get laws that make it very difficult to sell off-brand alternatives.
Not sure how exactly that works in the USA, but one of the PT’s government greatest achievement in Brazil was both providing legislation for selling off-patent drugs (called “generics”) and also making those tax free to encourage competition.
Lots of really important drugs (for example gut worms) became much more affordable in the span of some 5 years.
This is the type of legal subjugation of the American people that goes unpunished, Idk if this makes me sound like a PatSoc or not, but on God, anyone that sees themselves as patriots or proud of where they come from (I’m not personally) should have their piss brought to a boil by hearing this. Conservatives talk about competition in the market as if WE are being given a benefit of choice. Well, here in the US, companies “compete” all they want, they don’t lower insurance premiums, healthcare costs, or fucking anything. We just get drained and drained until someone does something horrific and fucked up and we talk about “mental health” for 2 weeks (not offering up any material condition changes or allowing more people to get in touch w social workers for free/very cheap) and when enough people forget, we act like nothing happened. The American populace is highly numbed to seeing or hearing about domestic terrorism unless it fits a narrative of a Muslim or illegal immigrant. If it’s a school shooting like Uvalde or a public massacre like in Vegas, we send our prayers, put up a link to Mindset .com or some shit to talk about “wellness”
I swear when they do shit like this it’s like they’re laughing in your face and taunting you that they can fuck you over as much as they want and you are powerless to do anything about it. Like they could have easily still made astronomical profits just by doubling, tripling, quadrupling the price. But no, they have to send a message about who is in charge.
